Disease characteristics at week 30* (TP2 ITT population)
| PF-SZ-IFX/PF-SZ-IFX (n=280) | Ref-IFX/Ref-IFX (n=143) | Ref-IFX/PF-SZ-IFX (n=143) | |
| Swollen joint count, mean (SD) | 4.9 (6.4) | 5.4 (6.6) | 4.7 (5.5) |
| Tender joint count, mean (SD) | 10.2 (11.7) | 10.3 (11.9) | 9.2 (8.9) |
| hs-CRP, mean (SD), mg/L | 13.0 (19.1) | 14.4 (21.1) | 10.6 (14.7) |
| Median (range) | 6.2 (0.2–154.0) | 5.8 (0.2–112.0) | 5.8 (0.2–94.3) |
| DAS28-CRP, mean (SD) | 3.8 (1.5) | 3.8 (1.4) | 3.8 (1.3) |
| HAQ-DI, mean (SD) | 1.0 (0.7) | 0.9 (0.7) | 1.0 (0.6) |
| Methotrexate dose, mean (SD), mg/week | 13.8 (4.2) | 13.8 (4.8) | 14.1 (4.3) |
| Corticosteroid use, n (%) | 156 (55.7) | 84 (58.7) | 81 (56.6) |
*Data were collected at week 30 study visit prior to the first infusion of study medication in TP2.
DAS28-CRP, Disease Activity Score in 28 Joints Based on High-Sensitivity C Reactive Protein; HAQ-DI, Health Assessment Questionnaire-Disability Index; hs-CRP, high-sensitivity C reactive protein; ITT, intent-to-treat; PF-SZ-IFX, PF-06438179/GP1111; ref-IFX, European reference infliximab; TP2, treatment period 2.